دورية أكاديمية
أعرض في EDS

Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma.

التفاصيل البيبلوغرافية
العنوان: Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma.
المؤلفون: Flesner BK; University of Missouri, College of Veterinary Medicine, Columbia, Missouri, USA., Wood GW; Elias Animal Health, Olathe, Kansas, USA., Gayheart-Walsten P; Xenometrics LLC, Stilwell, Kansas, USA., Sonderegger FL; Elias Animal Health, Olathe, Kansas, USA., Henry CJ; University of Missouri, College of Veterinary Medicine, Columbia, Missouri, USA., Tate DJ; University of Missouri, College of Veterinary Medicine, Columbia, Missouri, USA., Bechtel SM; University of Missouri, College of Veterinary Medicine, Columbia, Missouri, USA., Donnelly LL; University of Missouri, College of Veterinary Medicine, Columbia, Missouri, USA., Johnson GC; University of Missouri, College of Veterinary Medicine, Columbia, Missouri, USA., Kim DY; University of Missouri, College of Veterinary Medicine, Columbia, Missouri, USA., Wahaus TA; Elias Animal Health, Olathe, Kansas, USA., Bryan JN; University of Missouri, College of Veterinary Medicine, Columbia, Missouri, USA., Reyes N; Elias Animal Health, Olathe, Kansas, USA.
المصدر: Journal of veterinary internal medicine [J Vet Intern Med] 2020 Sep; Vol. 34 (5), pp. 2056-2067. Date of Electronic Publication: 2020 Jul 10.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley Periodicals Country of Publication: United States NLM ID: 8708660 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1939-1676 (Electronic) Linking ISSN: 08916640 NLM ISO Abbreviation: J Vet Intern Med Subsets: MEDLINE
أسماء مطبوعة: Publication: <2010-> : Malden, MA : Wiley Periodicals
Original Publication: Philadelphia : J.B. Lippincott Co., [c1987-
مواضيع طبية MeSH: Bone Neoplasms*/drug therapy , Bone Neoplasms*/veterinary , Dog Diseases*/drug therapy , Osteosarcoma*/drug therapy , Osteosarcoma*/veterinary, Interleukin-2/*therapeutic use, Animals ; Dogs ; Pets ; Prospective Studies ; T-Lymphocytes ; Treatment Outcome ; Vaccination/veterinary
مستخلص: Background: Osteosarcoma (OSA) in dogs is an aggressive bone tumor with frequent chemotherapy failure and translational relevance for human health.
Hypothesis/objectives: We hypothesized that dogs with OSA could be treated safely by ex vivo activated T-cells that were generated by autologous cancer vaccination and supported by interleukin-2 (IL-2) treatment with survival more than twice that reported for amputation alone.
Animals: Osteosarcoma-bearing dogs (n = 14) were enrolled in a single-arm prospective trial after complete staging before amputation. Four healthy dogs also were treated in a safety study.
Methods: Autologous cancer cell vaccinations were administered intradermally and dogs underwent leukapheresis. Mononuclear cell products were stimulated ex vivo with a T-cell-activating agent. Activated product was transfused and 5 SC IL-2 injections were administered q48h. Dogs were monitored for metastasis by thoracic radiography every 3 months.
Results: Autologous cancer cell vaccine and activated cellular therapy (ACT) products were successfully generated. Toxicity was minimal after premedicants were instituted before ACT. With premedication, all toxicities were grade I/II. Median disease-free interval for all dogs was 213 days. One dog developed cutaneous metastasis but then experienced spontaneous complete remission. Median survival time for all dogs was 415 days. Five dogs survived >730 days.
Conclusions and Clinical Importance: This immunotherapy protocol without cytotoxic chemotherapy is safe and tolerable. Compared to historical amputation reports, survival was notably prolonged in this group of patients. Additional prospective studies are warranted to elucidate active immunologic mechanisms and further improve disease response and survival.
(© 2020 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC. on behalf of the American College of Veterinary Internal Medicine.)
References: Nat Immunol. 2017 Feb 15;18(3):255-262. (PMID: 28198830)
Neurosurg Focus. 2000 Dec 15;9(6):e9. (PMID: 16817692)
Cancer Res. 1984 Apr;44(4):1671-6. (PMID: 6704973)
J Clin Oncol. 2015 Feb 20;33(6):540-9. (PMID: 25154820)
J Immunother Cancer. 2018 Dec 27;6(1):157. (PMID: 30587233)
J Immunol. 1987 Sep 15;139(6):2103-9. (PMID: 2957448)
Vet Comp Oncol. 2016 Dec;14(4):417-446. (PMID: 28530307)
ILAR J. 2014;55(1):169-81. (PMID: 24936037)
J Clin Oncol. 2003 Feb 15;21(4):624-30. (PMID: 12586798)
Adv Immunol. 1969;11:117-93. (PMID: 4392749)
Vet Comp Oncol. 2016 Mar;14(1):81-7. (PMID: 24118677)
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43. (PMID: 8097319)
Clin Cancer Res. 2016 Sep 1;22(17):4380-90. (PMID: 26994144)
Clin Cancer Res. 1999 Jul;5(7):1868-75. (PMID: 10430094)
Clin Immunol. 2008 Apr;127(1):66-77. (PMID: 18262845)
Cancer. 1997 Apr 1;79(7):1409-21. (PMID: 9083164)
Adv Immunol. 2016;130:279-94. (PMID: 26923004)
J Vet Intern Med. 2015 May-Jun;29(3):759-69. (PMID: 25929293)
J Am Vet Med Assoc. 1992 Apr 1;200(7):995-9. (PMID: 1577656)
J Small Anim Pract. 1977 May;18(5):313-26. (PMID: 267798)
Stat Med. 2001 Mar 30;20(6):859-66. (PMID: 11252008)
Vet Surg. 2006 Aug;35(6):518-33. (PMID: 16911152)
J Vet Intern Med. 2011 Nov-Dec;25(6):1406-13. (PMID: 22092635)
Adv Immunol. 2016;130:25-74. (PMID: 26922999)
J Clin Oncol. 1990 Nov;8(11):1858-67. (PMID: 2230873)
Vet Comp Oncol. 2018 Mar;16(1):E23-E29. (PMID: 28621057)
J Am Anim Hosp Assoc. 2005 Nov-Dec;41(6):382-7. (PMID: 16267062)
J Am Anim Hosp Assoc. 2009 Jan-Feb;45(1):33-8. (PMID: 19122062)
Sci Rep. 2012;2:249. (PMID: 22355761)
Cancer Chemother Pharmacol. 2000;46 Suppl:S67-72. (PMID: 10950151)
Cancer Chemother Pharmacol. 2002 Aug;50(2):131-6. (PMID: 12172978)
J Immunol. 1986 May 15;136(10):3891-8. (PMID: 3486223)
Blood. 2014 Apr 24;123(17):2625-35. (PMID: 24578504)
J Immunol. 1980 Aug;125(2):711-4. (PMID: 6156213)
J Natl Cancer Inst. 1989 Jun 21;81(12):935-8. (PMID: 2733037)
J Am Vet Med Assoc. 1993 Jan 15;202(2):304-6. (PMID: 8428842)
Cancer Res. 1997 Apr 15;57(8):1537-46. (PMID: 9108457)
J Immunother. 2014 Oct;37(8):407-15. (PMID: 25198528)
Cancer Res. 1953 Dec;13(12):835-7. (PMID: 13116120)
Transplant Proc. 1973 Dec;5(4):1441-5. (PMID: 4204523)
Vet Anaesth Analg. 2013 Jul;40(4):403-9. (PMID: 23448317)
Ann Surg Oncol. 2005 Dec;12(12):1073-83. (PMID: 16252138)
Clin Orthop Relat Res. 1991 Sep;(270):159-68. (PMID: 1884536)
J Vet Intern Med. 2020 Sep;34(5):2056-2067. (PMID: 32649801)
BMC Vet Res. 2012 May 15;8:56. (PMID: 22587466)
Science. 2015 Apr 3;348(6230):69-74. (PMID: 25838375)
Nature. 2013 Aug 22;500(7463):415-21. (PMID: 23945592)
Anticancer Res. 2007 Jan-Feb;27(1A):155-64. (PMID: 17352227)
J Vet Intern Med. 2014 Mar-Apr;28(2):529-37. (PMID: 24467413)
J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):153-65. (PMID: 8471590)
J Clin Oncol. 2003 Mar 1;21(5):884-90. (PMID: 12610189)
Science. 2016 May 6;352(6286):658-60. (PMID: 27151852)
J Vet Intern Med. 1996 Mar-Apr;10(2):76-81. (PMID: 8683484)
Vet Comp Oncol. 2014 Dec;12(4):249-57. (PMID: 22985083)
J Natl Cancer Inst. 1957 Jun;18(6):769-78. (PMID: 13502695)
J Vet Intern Med. 1991 Jul-Aug;5(4):205-10. (PMID: 1941754)
Semin Oncol. 2015 Jun;42(3):488-94. (PMID: 25965368)
Science. 2015 Apr 3;348(6230):56-61. (PMID: 25838373)
فهرسة مساهمة: Keywords: canine; immunotherapy; interleukin 2; leukapheresis; osteosarcoma
المشرفين على المادة: 0 (Interleukin-2)
تواريخ الأحداث: Date Created: 20200711 Date Completed: 20210625 Latest Revision: 20220531
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7517513
DOI: 10.1111/jvim.15852
PMID: 32649801
قاعدة البيانات: MEDLINE
الوصف
تدمد:1939-1676
DOI:10.1111/jvim.15852